Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Cara Therapeutics stock opened at $0.27 on Friday. The business has a fifty day moving average price of $0.29 and a 200-day moving average price of $0.35. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.31. The stock has a market capitalization of $14.59 million, a price-to-earnings ratio of -0.15 and a beta of 0.64.

Hedge Funds Weigh In On Cara Therapeutics

Several hedge funds have recently modified their holdings of CARA. FMR LLC grew its position in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Cara Therapeutics during the third quarter worth $29,000. Finally, Disciplined Growth Investors Inc. MN grew its holdings in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares during the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.